Drug Approval | November 26, 2021
Aadi Bioscience secures U.S FDA approval of its first product Fyarro
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
Biocon Biologics and Viatris co-developed the products
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
